tru Independence LLC Sells 690 Shares of CVS Health Co. (NYSE:CVS)

tru Independence LLC lowered its stake in shares of CVS Health Co. (NYSE:CVS) by 0.9% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 72,784 shares of the pharmacy operator’s stock after selling 690 shares during the period. CVS Health accounts for 1.7% of tru Independence LLC’s holdings, making the stock its 21st biggest position. tru Independence LLC’s holdings in CVS Health were worth $5,805,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Atticus Wealth Management LLC raised its stake in CVS Health by 149.0% in the 4th quarter. Atticus Wealth Management LLC now owns 366 shares of the pharmacy operator’s stock valued at $29,000 after acquiring an additional 219 shares during the period. USA Financial Formulas raised its stake in CVS Health by 573.2% in the 4th quarter. USA Financial Formulas now owns 377 shares of the pharmacy operator’s stock valued at $30,000 after acquiring an additional 321 shares during the period. Ables Iannone Moore & Associates Inc. bought a new stake in CVS Health in the 4th quarter valued at $32,000. Creekmur Asset Management LLC bought a new stake in CVS Health in the 4th quarter valued at $34,000. Finally, Steph & Co. raised its stake in CVS Health by 192.0% in the 1st quarter. Steph & Co. now owns 438 shares of the pharmacy operator’s stock valued at $35,000 after acquiring an additional 288 shares during the period. Institutional investors own 80.66% of the company’s stock.

Insider Buying and Selling at CVS Health

In other news, Director Edward J. Ludwig bought 1,000 shares of the stock in a transaction on Thursday, May 2nd. The shares were purchased at an average cost of $53.88 per share, for a total transaction of $53,880.00. Following the completion of the purchase, the director now directly owns 21,630 shares in the company, valued at approximately $1,165,424.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.24% of the company’s stock.

CVS Health Stock Down 0.9 %

CVS Health stock traded down $0.52 during mid-day trading on Tuesday, reaching $57.63. The stock had a trading volume of 2,170,480 shares, compared to its average volume of 11,995,189. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.61 and a current ratio of 0.81. CVS Health Co. has a fifty-two week low of $52.77 and a fifty-two week high of $83.25. The stock’s 50-day simple moving average is $59.56 and its 200-day simple moving average is $70.13. The firm has a market capitalization of $72.35 billion, a PE ratio of 10.22, a price-to-earnings-growth ratio of 0.56 and a beta of 0.52.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, May 1st. The pharmacy operator reported $1.31 EPS for the quarter, missing analysts’ consensus estimates of $1.69 by ($0.38). The business had revenue of $88.44 billion for the quarter, compared to the consensus estimate of $89.33 billion. CVS Health had a return on equity of 13.53% and a net margin of 2.03%. The business’s revenue was up 3.7% compared to the same quarter last year. During the same quarter last year, the business posted $2.20 earnings per share. On average, sell-side analysts forecast that CVS Health Co. will post 7.02 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CVS has been the topic of a number of research reports. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $58.00 price objective on shares of CVS Health in a report on Wednesday, June 12th. Mizuho decreased their price objective on CVS Health from $86.00 to $72.00 and set a “buy” rating on the stock in a report on Thursday, May 2nd. TD Cowen lowered CVS Health from a “buy” rating to a “hold” rating and decreased their price objective for the company from $99.00 to $59.00 in a report on Tuesday, May 7th. Baird R W raised CVS Health to a “hold” rating in a report on Thursday, May 30th. Finally, Argus reduced their target price on CVS Health from $100.00 to $80.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th. Eleven equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, CVS Health has a consensus rating of “Moderate Buy” and an average price target of $75.05.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.